Ornithine Carbamoyltransferase Deficiency

Mendelian MONDO:0010703 Pathograph 31 Urea Cycle Disorder Inborn Error of Metabolism

Ornithine carbamoyltransferase deficiency (OTCD) is the most common urea cycle disorder, caused by pathogenic variants in the X-linked OTC gene. The encoded mitochondrial enzyme catalyzes the conversion of carbamoyl phosphate and ornithine to citrulline. Deficiency impairs ureagenesis, producing episodic or persistent hyperammonemia with risk of severe neurologic injury. Hemizygous males typically present with neonatal-onset disease, whereas heterozygous females and males with partial enzyme deficiency may present with later-onset intermittent hyperammonemia triggered by catabolic stress.

Ask OpenScientist

Ask a research question about Ornithine Carbamoyltransferase Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
13
Phenotypes
31
Pathograph
2
Genes
6
Treatments
1
Deep Research
⚙

Pathophysiology

6
Ornithine carbamoyltransferase molecular function deficiency
Pathogenic OTC variants reduce ornithine carbamoyltransferase enzymatic activity in hepatic mitochondria.
hepatocyte link
OTC link
ornithine carbamoyltransferase activity link ↓ DECREASED
liver link
Downstream
Impaired citrulline synthesis and reduced urea cycle flux Reduced OTC activity limits carbamoyl phosphate utilization in ureagenesis.
Show evidence (2 references)
PMID:31441224 SUPPORT Human Clinical
"Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder."
Supports OTCD as a urea-cycle enzyme deficiency disorder.
PMID:31110235 SUPPORT Other
"carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix"
Confirms mitochondrial matrix localization of OTC enzyme.
Impaired citrulline synthesis and reduced urea cycle flux
Reduced OTC activity lowers conversion of ornithine and carbamoyl phosphate to citrulline, decreasing urea cycle throughput and predisposing to hyperammonemia.
urea cycle link ↓ DECREASED
Downstream
Systemic ammonia accumulation Reduced urea cycle flux prevents hepatic ammonia disposal and raises systemic ammonia.
Low plasma citrulline Reduced OTC product formation lowers plasma citrulline in many early-onset cases.
Citrulline OTC deficiency reduces citrulline synthesis and lowers citrulline or citrulline-derived screening ratios.
Hepatic failure Severe early-onset OTCD can include liver failure during metabolic decompensation.
Carbamoyl phosphate diversion to pyrimidine pathway Carbamoyl phosphate that cannot be used for OTC-dependent citrulline synthesis is shunted toward pyrimidine byproducts.
Show evidence (1 reference)
PMID:39328593 SUPPORT Human Clinical
"OTCD typically leads to mitochondrial enzyme dysfunction, preventing the synthesis of citrulline from carbamoyl phosphate and ornithine"
Directly supports the enzymatic defect blocking citrulline synthesis.
Systemic ammonia accumulation
Impaired OTC-dependent ureagenesis allows blood ammonia to rise. Ammonia detoxification through glutamine synthesis raises glutamine and provides the proximal biochemical driver of hyperammonemic CNS injury.
Downstream
Hyperammonemic cerebral injury via astrocyte swelling Systemic ammonia crosses into brain and is converted to glutamine, driving astrocyte swelling.
Hyperammonemia Systemic ammonia accumulation manifests clinically as hyperammonemia.
Ammonia Impaired ureagenesis increases circulating ammonium/ammonia.
Glutamine Excess ammonia is detoxified through glutamine synthesis, increasing plasma and brain glutamine.
Hyperglutaminemia Ammonia detoxification burden produces clinically detectable hyperglutaminemia.
Show evidence (2 references)
PMID:39328593 SUPPORT Human Clinical
"preventing the synthesis of citrulline from carbamoyl phosphate and ornithine, and is characterized by a remarkable increase in blood ammonia."
Clinical OTCD evidence links impaired citrulline synthesis to increased blood ammonia.
PMID:32628763 SUPPORT Human Clinical
"The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
Human OTCD report summarizes the ammonia, glutamine, citrulline, and orotic-acid biochemical pattern.
Hyperammonemic cerebral injury via astrocyte swelling
Recurrent hyperammonemia causes astrocyte swelling and cerebral edema through glutamine accumulation. In brain, glutamine synthesis is the only route of ammonia detoxification, and excess glutamine acts as an osmolyte causing astrocyte swelling and cerebral edema.
astrocyte link
L-glutamine metabolic process link ↑ INCREASED
brain link
Downstream
Ammonia-induced oxidative stress and mitochondrial dysfunction Ammonia and glutamine-driven astrocyte swelling promote downstream oxidative and mitochondrial stress in the CNS.
Encephalopathy Ammonia-driven brain swelling and neurotransmission toxicity cause metabolic encephalopathy.
Cerebral edema Astrocytic glutamine accumulation acts osmotically, producing brain swelling and cerebral edema.
Coma Severe hyperammonemic brain edema and intracranial hypertension can progress to coma.
Seizures Hyperammonemic neurologic injury can manifest with seizures in early-onset OTCD.
Vomiting Hyperammonemic decompensation can begin with vomiting before deterioration in consciousness.
Lethargy Hyperammonemic CNS dysfunction reduces arousal and can progress to coma.
Behavioral abnormalities Slower or intermittent hyperammonemia can cause behavioral and psychiatric manifestations.
Show evidence (4 references)
PMID:36128655 SUPPORT Human Clinical
"Its clinical manifestations are mainly central nervous system dysfunction caused by high blood ammonia."
Supports ammonia-driven CNS injury as a core downstream mechanism.
PMID:34665389 SUPPORT Other
"severe damage to the central nervous system due to the toxic effects exerted by ammonia on the astrocytes"
Directly supports astrocyte-mediated ammonia neurotoxicity.
PMID:35733937 SUPPORT Other
"in brain glutamine synthesis is the only route of ammonia detoxification, hyperammonemia is as a rule associated with increased brain glutamine content (glutaminosis)"
Supports the glutamine trapping hypothesis and osmotic astrocyte swelling mechanism.
+ 1 more reference
Ammonia-induced oxidative stress and mitochondrial dysfunction
Hyperammonemia induces oxidative stress and mitochondrial dysfunction in the CNS, contributing to neuronal energy failure and cumulative neurodevelopmental impairment.
response to oxidative stress link ↑ INCREASED
Downstream
Global developmental delay Severe or recurrent hyperammonemic CNS injury can leave persistent neurodevelopmental sequelae.
Show evidence (1 reference)
PMID:34665389 SUPPORT Other
"Ammonia is a neurotoxic compound which is detoxified through liver enzymes from urea cycle."
Supports the neurotoxic role of ammonia when hepatic detoxification is impaired.
Carbamoyl phosphate diversion to pyrimidine pathway
When OTC cannot utilize carbamoyl phosphate for citrulline synthesis, substrate shunting into pyrimidine synthesis produces urinary pyrimidine byproducts and contributes to increased urine orotic acid in OTCD.
Downstream
Uracil Carbamoylphosphate shunting to pyrimidine synthesis increases urinary uracil in OTCD.
Orotic acid OTCD has increased urine orotic acid as part of the pyrimidine-diversion biochemical pattern.
Oroticaciduria Increased urinary orotic acid manifests clinically as oroticaciduria.
Show evidence (2 references)
PMID:32628763 SUPPORT Human Clinical
"UU can accumulate in UCDs, due to shunting of carbamoylphosphate to pyrimidine synthesis (Fig. 1)."
OTCD case-based evidence supports carbamoylphosphate shunting into pyrimidine synthesis.
PMID:32628763 SUPPORT Human Clinical
"The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
Human OTCD report supports increased urinary orotic acid as a major biochemical hallmark.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Ornithine Carbamoyltransferase Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Digestive 2
Vomiting FREQUENT Vomiting (HP:0002013)
Show evidence (1 reference)
PMID:36128655 SUPPORT Human Clinical
"His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma."
Directly supports vomiting as an early symptom in hyperammonemic decompensation.
Hepatic failure OCCASIONAL Hepatic failure (HP:0001399)
Show evidence (1 reference)
PMID:39256843 SUPPORT Human Clinical
"Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure."
Directly reports liver failure as a clinical feature in early-onset OTCD.
Genitourinary 1
Oroticaciduria VERY_FREQUENT Oroticaciduria (HP:0003218)
Oroticaciduria is a well-established diagnostic marker differentiating OTCD from CPS1 deficiency, with urinary pyrimidine byproducts reflecting carbamoylphosphate shunting to pyrimidine synthesis.
Show evidence (2 references)
PMID:32410394 SUPPORT Human Clinical
"The urinary orotic acid level was 132.92 μmol/mmol creatinine (reference: 0.0–1.5 μmol/mmol creatinine)."
Infant OTCD case evidence supports markedly elevated urinary orotic acid.
PMID:32628763 SUPPORT Human Clinical
"The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
Human OTCD report identifies increased urinary orotic acid as a major biochemical hallmark.
Metabolism 4
Hyperammonemia VERY_FREQUENT Hyperammonemia (HP:0001987)
Show evidence (2 references)
PMID:31441224 SUPPORT Human Clinical
"Maternal OTCD can lead to life-threatening hyperammonemia if untreated."
Confirms hyperammonemia as a major clinical risk in OTCD.
PMID:37146589 SUPPORT Human Clinical
"Individuals with neonatal onset appear normal at birth but rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"
Confirms hyperammonemia as the pivotal early clinical event in neonatal OTCD.
Cerebral edema FREQUENT Cerebral edema (HP:0002181)
Show evidence (2 references)
PMID:37146589 SUPPORT Human Clinical
"rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"
Directly names cerebral edema as a complication of hyperammonemia in OTCD.
PMID:33409766 SUPPORT Human Clinical
"emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%"
Quantifies the high risk of cerebral edema at severe ammonia levels.
Hyperglutaminemia VERY_FREQUENT Hyperglutaminemia (HP:0003217)
Show evidence (1 reference)
PMID:39220945 SUPPORT Human Clinical
"all ten early-onset cases had glutamine concentrations above the upper limit"
Directly documents hyperglutaminemia in all early-onset OTCD cases.
Low plasma citrulline FREQUENT Low plasma citrulline (HP:0003572)
Show evidence (1 reference)
PMID:39220945 SUPPORT Human Clinical
"only five of them had citrulline concentrations below the lower limit of the reference interval"
Documents low citrulline in early-onset OTCD, though not universally present.
Nervous System 6
Encephalopathy FREQUENT Encephalopathy (HP:0001298)
Show evidence (2 references)
PMID:36128655 SUPPORT Human Clinical
"Its clinical manifestations are mainly central nervous system dysfunction caused by high blood ammonia."
Supports encephalopathic CNS dysfunction in OTCD.
PMID:33409766 SUPPORT Human Clinical
"Hyperammonemia caused by a disorder of the urea cycle is a rare cause of metabolic encephalopathy that may be underdiagnosed by the adult intensivists because of its rarity."
Directly identifies UCD-related hyperammonemia as a cause of metabolic encephalopathy.
Lethargy FREQUENT Lethargy (HP:0001254)
Show evidence (1 reference)
PMID:36128655 SUPPORT Human Clinical
"His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma."
Supports severe neurologic decline during OTCD decompensation episodes.
Seizures FREQUENT Seizure (HP:0001250)
Show evidence (1 reference)
PMID:39256843 SUPPORT Human Clinical
"Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure."
Directly reports seizures as a clinical manifestation in early-onset OTCD.
Coma FREQUENT Coma (HP:0001259)
Show evidence (2 references)
PMID:37146589 SUPPORT Human Clinical
"rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"
Directly supports coma as a progression of hyperammonemia in OTCD.
PMID:36128655 SUPPORT Human Clinical
"the disease progressed rapidly and finally resulted in a coma"
Case report documenting progression to coma in late-onset OTCD.
Global developmental delay OCCASIONAL Global developmental delay (HP:0001263)
Show evidence (1 reference)
PMID:36128655 SUPPORT Human Clinical
"However, the child is currently mentally retarded, and the language center has not yet fully recovered."
Supports persistent neurodevelopmental impairment after severe OTCD CNS injury.
Behavioral abnormalities OCCASIONAL Atypical behavior (HP:0000708)
Behavioral disorders reported in 35% of adult-onset UCD presentations in systematic reviews.
Show evidence (1 reference)
PMID:33409766 SUPPORT Human Clinical
"Increased serotonin production may contribute to behavioral abnormalities, migraine, headaches, and changes in cerebral blood flow"
Clinical review evidence supports behavioral abnormalities in slower hyperammonemic states.
🧬

Genetic Associations

2
OTC variants
X-linked inheritance
Show evidence (4 references)
PMID:31441224 SUPPORT Human Clinical
"Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder."
Supports OTC genetic etiology and inheritance architecture.
PMID:37146589 SUPPORT Human Clinical
"This rare but highly actionable disease can present with severe neonatal onset in males or with later onset in either sex."
Supports genotype-phenotype correlation with variable onset and severity.
PMID:37146589 SUPPORT In Vitro
"our assay distinguishes known benign from pathogenic variants and variants with neonatal onset from late-onset disease presentation"
Demonstrates functional assay-based classification of variant severity.
+ 1 more reference
OTC (Pathogenic Variants)
Show evidence (1 reference)
CGGV:assertion_132fafbf-bb34-447c-9f6a-65803679eeb8-2019-10-29T181325.783Z SUPPORT Other
"OTC | HGNC:8512 | ornithine carbamoyltransferase deficiency | MONDO:0010703 | XL | Definitive"
ClinGen classifies the OTC-ornithine carbamoyltransferase deficiency gene-disease relationship as definitive with X-linked inheritance.
💊

Treatments

6
Protein-restricted diet
Action: dietary intervention MAXO:0000088
Dietary nitrogen control tailored to age and growth requirements to reduce ammonia production.
Mechanism Target:
INHIBITS Systemic ammonia accumulation — Protein restriction reduces nitrogen substrate load and lowers ammonia production pressure.
Show evidence (1 reference)
PMID:33409766 SUPPORT Human Clinical
"the goal of treatment being to reduce ammonia production and accelerate elimination via alternative pathways"
Systematic clinical review supports diet and treatment as ammonia-lowering strategies for urea-cycle defects.
Show evidence (2 references)
PMID:37626723 SUPPORT Other
"current dietary and medical treatments may not be sufficient to prevent hyperammonemic episodes"
Supports dietary treatment as a standard component of OTCD management, though acknowledging its limitations.
PMID:33409766 SUPPORT Human Clinical
"Treatment consists in adapted nutrition, scavenging agents and dialysis."
Confirms adapted nutrition as a core treatment component for UCD.
Nitrogen scavenger therapy
Action: nitrogen scavenger therapy Ontology label: Pharmacotherapy NCIT:C15986
Agent: sodium benzoate ↗ sodium phenylbutyrate ↗ glycerol phenylbutyrate ↗
Pharmacologic ammonia-scavenging agents (sodium benzoate, sodium phenylbutyrate, glycerol phenylbutyrate) for chronic and acute management.
Mechanism Target:
BYPASSES Impaired citrulline synthesis and reduced urea cycle flux — Nitrogen scavengers divert nitrogen into urinary excretion products that do not require normal urea-cycle flux.
Show evidence (1 reference)
PMID:33409766 SUPPORT Human Clinical
"Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle"
Clinical review evidence supports nitrogen scavengers as bypassing the urea cycle for nitrogen elimination.
Show evidence (2 references)
PMID:33409766 SUPPORT Human Clinical
"Treatment consists in adapted nutrition, scavenging agents and dialysis."
Confirms scavenging agents as a standard treatment modality.
PMID:37626723 SUPPORT Other
"current dietary and medical treatments may not be sufficient to prevent hyperammonemic episodes"
Supports pharmacologic treatment as standard care while noting its limitations.
Arginine supplementation
Action: nutritional supplementation MAXO:0000106
Agent: L-arginine ↗
L-arginine supplementation to provide substrate for the urea cycle downstream of the OTC block.
Mechanism Target:
MODULATES Impaired citrulline synthesis and reduced urea cycle flux — Arginine supplementation supports downstream urea-cycle metabolites and limits proteolysis during impaired ureagenesis.
Show evidence (1 reference)
PMID:33409766 SUPPORT Human Clinical
"Supplementation with L-Arginine or Citrulline is recommended to promote an alternative pathway of metabolism"
Clinical review evidence supports arginine/citrulline supplementation as an alternative pathway support in UCD management.
Show evidence (1 reference)
PMID:33409766 SUPPORT Human Clinical
"Fifteen patients received l-arginine"
Documents L-arginine use in the systematic review of adult UCD case reports.
Acute hyperammonemia management
Action: supportive care MAXO:0000950
Rapid crisis-directed supportive management including protein restriction, glucose infusion, nitrogen scavengers, and emergent hemodialysis when ammonia exceeds 200 micromol/L.
Mechanism Target:
INHIBITS Hyperammonemic cerebral injury via astrocyte swelling — Emergency dialysis and ammonia-lowering treatment reduce ammonia exposure to prevent brain edema and death.
Show evidence (1 reference)
PMID:33409766 SUPPORT Human Clinical
"In hyperammonemia associated with urea cycle disorders, treatment with hemodialysis can reverse encephalopathy and prevent brain edema and death"
Clinical review evidence supports hemodialysis as a mechanism-targeted acute intervention against hyperammonemic cerebral injury.
Show evidence (2 references)
PMID:31441224 SUPPORT Human Clinical
"Maternal OTCD can lead to life-threatening hyperammonemia if untreated."
Supports urgent supportive and ammonia-lowering intervention during crises.
PMID:33409766 SUPPORT Human Clinical
"emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%"
Provides clinical threshold for emergent hemodialysis in acute hyperammonemia.
Liver transplantation
Action: organ transplantation MAXO:0010039
Curative metabolic option for selected severe phenotypes; restores full urea cycle capacity and eliminates hyperammonemic risk.
Mechanism Target:
RESTORES Ornithine carbamoyltransferase molecular function deficiency — Liver transplantation supplies hepatic urea-cycle capacity that corrects the ammonia metabolism defect.
Show evidence (1 reference)
PMID:36128655 SUPPORT Human Clinical
"liver transplantation can fundamentally solve the problem of ammonia metabolism in the liver"
OTCD liver-transplant case review supports restoration of hepatic ammonia metabolism.
Show evidence (3 references)
PMID:36128655 SUPPORT Human Clinical
"For OTCD patients with central nervous system injury, liver transplantation can fundamentally solve the problem of ammonia metabolism in the liver and avoids further damage to the central nervous system caused by hyperammonemia."
Directly supports liver transplantation as a disease-modifying option in severe OTCD.
PMID:37626723 SUPPORT Other
"liver transplantation is the only curative choice but is not widely available due to donor shortage, the need for life-long immunosuppression and technical challenges"
Confirms liver transplantation as the only curative treatment while noting practical limitations.
PMID:39256843 SUPPORT Human Clinical
"Three patients survived, and two of them underwent liver transplantation."
Documents liver transplantation as a life-saving intervention in OTCD.
Genetic counseling
Action: genetic counseling MAXO:0000079
Genetic counseling for X-linked inheritance pattern, carrier testing in at-risk females, and prenatal/preconception planning.
Show evidence (1 reference)
PMID:31441224 SUPPORT Human Clinical
"Maternal OTCD is associated with high maternal and neonatal morbidity and mortality when diagnosis is made during pregnancy compared to when diagnosis is known prior to pregnancy."
Strongly supports the value of pre-pregnancy diagnosis and genetic counseling for carrier females.
🔬

Biochemical Markers

5
Ammonia (Increased)
Context: Hyperammonemia from impaired urea cycle in OTCD
Pathograph Readouts
Readout Of Systemic ammonia accumulation Positive Diagnostic
Blood ammonia reports the proximal failure of hepatic ammonia disposal caused by reduced OTC-dependent urea-cycle flux.
Readout Of Hyperammonemia Positive Diagnostic
Blood ammonia is the direct biochemical readout of hyperammonemia.
Readout Of Hyperammonemic cerebral injury via astrocyte swelling Positive Monitoring
Plasma ammonia severity tracks risk of hyperammonemic cerebral edema and neurologic injury.
Show evidence (2 references)
PMID:37146589 SUPPORT Human Clinical
"Individuals with neonatal onset appear normal at birth but rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"
Confirms hyperammonemia as the cardinal biochemical abnormality in OTCD.
PMID:39256843 SUPPORT Human Clinical
"elevated blood ammonia levels serve as a crucial diagnostic clue for OTCD"
Directly identifies elevated ammonia as a key diagnostic marker.
Glutamine (Increased)
Context: Elevated plasma glutamine from ammonia detoxification via glutamine synthetase
Pathograph Readouts
Readout Of Systemic ammonia accumulation Positive Monitoring
Elevated glutamine reports ammonia detoxification burden downstream of impaired ureagenesis.
Readout Of Hyperglutaminemia Positive Diagnostic
Plasma glutamine is the direct biochemical readout of hyperglutaminemia.
Readout Of Hyperammonemic cerebral injury via astrocyte swelling Positive Monitoring
Brain or plasma glutamine tracks the glutamine-osmolyte mechanism driving astrocyte swelling.
Show evidence (2 references)
PMID:39220945 SUPPORT Human Clinical
"all ten early-onset cases had glutamine concentrations above the upper limit"
Directly documents elevated glutamine in all early-onset OTCD cases.
PMID:12136059 SUPPORT Human Clinical
"The glutamine (Gln) plus glutamate concentration was increased in four patients, which progressed in proportion to the clinical stage."
Brain MRS data showing progressive glutamine accumulation correlating with clinical severity.
Citrulline (Decreased)
Context: Low or low-normal plasma citrulline from impaired OTC enzymatic product formation
Pathograph Readouts
Readout Of Impaired citrulline synthesis and reduced urea cycle flux Negative Diagnostic
Low citrulline reports reduced product formation at the OTC-catalyzed urea-cycle step.
Readout Of Low plasma citrulline Negative Diagnostic
Plasma citrulline is the direct biochemical readout of low citrulline.
Show evidence (2 references)
PMID:39220945 SUPPORT Human Clinical
"only five of them had citrulline concentrations below the lower limit of the reference interval"
Documents low citrulline in a proportion of early-onset OTCD cases.
PMID:39220945 SUPPORT Human Clinical
"The Cit/Phe ratio was decreased, and the Gln/Cit and Met/Cit ratios were increased in all early-onset OTCD cases"
Supports abnormal citrulline ratios as reliable screening markers.
Uracil (Increased)
Context: Increased urinary uracil accompanying carbamoylphosphate shunting to pyrimidine synthesis
Pathograph Readouts
Readout Of Carbamoyl phosphate diversion to pyrimidine pathway Positive Diagnostic
Urinary uracil reports carbamoyl phosphate shunting into pyrimidine synthesis when OTC flux is blocked.
Show evidence (2 references)
PMID:32628763 SUPPORT Human Clinical
"Organic acids revealed increased urinary uracil (UU, 36 mg/g Cr)(RI:0-21) concerning for ornithine transcarbamylase deficiency (OTCD)."
OTCD case evidence directly reports increased urinary uracil.
PMID:32628763 SUPPORT Human Clinical
"UU may be more reliable than OA for late-onset OTCD during acute and quiescent phases."
Human OTCD report supports urinary uracil as a useful biomarker, particularly in late-onset disease.
Orotic acid (Increased)
Context: Elevated urinary orotic acid accompanying carbamoylphosphate shunting to pyrimidine synthesis
Pathograph Readouts
Readout Of Carbamoyl phosphate diversion to pyrimidine pathway Positive Diagnostic
Elevated urinary orotic acid reports pyrimidine byproduct formation from carbamoyl phosphate diversion.
Readout Of Oroticaciduria Positive Diagnostic
Urinary orotic acid is the direct biochemical readout of oroticaciduria.
Show evidence (2 references)
PMID:32410394 SUPPORT Human Clinical
"The urinary orotic acid level was 132.92 μmol/mmol creatinine (reference: 0.0–1.5 μmol/mmol creatinine)."
Infant OTCD case evidence directly supports elevated urinary orotic acid.
PMID:32628763 SUPPORT Human Clinical
"The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
Human OTCD report supports increased urine orotic acid as a hallmark biochemical abnormality.
{ }

Source YAML

click to show 
name: Ornithine Carbamoyltransferase Deficiency
creation_date: '2026-02-23T00:00:00Z'
updated_date: '2026-05-20T06:45:18Z'
category: Mendelian
synonyms:
- OTC deficiency
- Ornithine transcarbamylase deficiency
- OTCD
description: >
  Ornithine carbamoyltransferase deficiency (OTCD) is the most common urea cycle
  disorder, caused by pathogenic variants in the X-linked OTC gene. The encoded
  mitochondrial enzyme catalyzes the conversion of carbamoyl phosphate and
  ornithine to citrulline. Deficiency impairs ureagenesis, producing episodic or
  persistent hyperammonemia with risk of severe neurologic injury. Hemizygous
  males typically present with neonatal-onset disease, whereas heterozygous
  females and males with partial enzyme deficiency may present with later-onset
  intermittent hyperammonemia triggered by catabolic stress.
disease_term:
  preferred_term: ornithine carbamoyltransferase deficiency
  term:
    id: MONDO:0010703
    label: ornithine carbamoyltransferase deficiency
parents:
- Urea Cycle Disorder
- Inborn Error of Metabolism
prevalence:
- population: Live births
  percentage: 1 in 14,000 live births
  notes: >-
    Review-based clinical literature commonly cites OTCD as the most frequent
    inherited urea-cycle disorder with incidence around 1 in 14,000 live
    births.
  evidence:
  - reference: PMID:35204506
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ornithine transcarbamylase (OTC) deficiency is the most common inherited metabolic disorder in urea cycles with an incidence of 1:14,000 live births."
    explanation: This review provides a direct incidence estimate for OTCD and identifies it as the most common urea-cycle disorder.
pathophysiology:
- name: Ornithine carbamoyltransferase molecular function deficiency
  description: >
    Pathogenic OTC variants reduce ornithine carbamoyltransferase enzymatic
    activity in hepatic mitochondria.
  genes:
  - preferred_term: OTC
    term:
      id: hgnc:8512
      label: OTC
  molecular_functions:
  - preferred_term: ornithine carbamoyltransferase activity
    term:
      id: GO:0004585
      label: ornithine carbamoyltransferase activity
    modifier: DECREASED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:31441224
    reference_title: "Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder."
    explanation: Supports OTCD as a urea-cycle enzyme deficiency disorder.
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix"
    explanation: Confirms mitochondrial matrix localization of OTC enzyme.
  downstream:
  - target: Impaired citrulline synthesis and reduced urea cycle flux
    description: Reduced OTC activity limits carbamoyl phosphate utilization in ureagenesis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39328593
      reference_title: "In-depth analysis of OTC A208T case induced by OTC gene mutation and research on the prediction and simulation of the impact on protein function."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "OTCD typically leads to mitochondrial enzyme dysfunction, preventing the synthesis of citrulline from carbamoyl phosphate and ornithine"
      explanation: Patient-oriented OTCD report directly connects OTC dysfunction to blocked citrulline synthesis from carbamoyl phosphate and ornithine.
- name: Impaired citrulline synthesis and reduced urea cycle flux
  description: >
    Reduced OTC activity lowers conversion of ornithine and carbamoyl phosphate
    to citrulline, decreasing urea cycle throughput and predisposing to
    hyperammonemia.
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
    modifier: DECREASED
  chemical_entities:
  - preferred_term: carbamoyl phosphate
    term:
      id: CHEBI:17672
      label: carbamoyl phosphate
    modifier: ABNORMAL
  - preferred_term: citrulline
    term:
      id: CHEBI:18211
      label: citrulline
    modifier: DECREASED
  evidence:
  - reference: PMID:39328593
    reference_title: "In-depth analysis of OTC A208T case induced by OTC gene mutation and research on the prediction and simulation of the impact on protein function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "OTCD typically leads to mitochondrial enzyme dysfunction, preventing the synthesis of citrulline from carbamoyl phosphate and ornithine"
    explanation: Directly supports the enzymatic defect blocking citrulline synthesis.
  downstream:
  - target: Systemic ammonia accumulation
    description: Reduced urea cycle flux prevents hepatic ammonia disposal and raises systemic ammonia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39328593
      reference_title: "In-depth analysis of OTC A208T case induced by OTC gene mutation and research on the prediction and simulation of the impact on protein function."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "preventing the synthesis of citrulline from carbamoyl phosphate and ornithine, and is characterized by a remarkable increase in blood ammonia."
      explanation: OTCD evidence links blocked citrulline synthesis directly to increased blood ammonia.
  - target: Low plasma citrulline
    description: Reduced OTC product formation lowers plasma citrulline in many early-onset cases.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39220945
      reference_title: "A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in Vietnam."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "only five of them had citrulline concentrations below the lower limit of the reference interval"
      explanation: Early-onset OTCD cohort evidence supports reduced citrulline as a biochemical manifestation.
  - target: Citrulline
    description: OTC deficiency reduces citrulline synthesis and lowers citrulline or citrulline-derived screening ratios.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39220945
      reference_title: "A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in Vietnam."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The Cit/Phe ratio was decreased, and the Gln/Cit and Met/Cit ratios were increased in all early-onset OTCD cases"
      explanation: Early-onset OTCD data support citrulline-related biochemical abnormalities downstream of impaired OTC flux.
  - target: Hepatic failure
    description: Severe early-onset OTCD can include liver failure during metabolic decompensation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39256843
      reference_title: "Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure."
      explanation: Clinical cohort evidence supports liver failure as a severe early-onset OTCD manifestation.
  - target: Carbamoyl phosphate diversion to pyrimidine pathway
    description: Carbamoyl phosphate that cannot be used for OTC-dependent citrulline synthesis is shunted toward pyrimidine byproducts.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32628763
      reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "UU can accumulate in UCDs, due to shunting of carbamoylphosphate to pyrimidine synthesis (Fig. 1)."
      explanation: OTCD case-based evidence supports carbamoylphosphate shunting into pyrimidine synthesis as the diversion mechanism.
- name: Systemic ammonia accumulation
  description: >
    Impaired OTC-dependent ureagenesis allows blood ammonia to rise. Ammonia
    detoxification through glutamine synthesis raises glutamine and provides the
    proximal biochemical driver of hyperammonemic CNS injury.
  chemical_entities:
  - preferred_term: ammonium
    term:
      id: CHEBI:28938
      label: ammonium
    modifier: INCREASED
  - preferred_term: glutamine
    term:
      id: CHEBI:28300
      label: glutamine
    modifier: INCREASED
  evidence:
  - reference: PMID:39328593
    reference_title: "In-depth analysis of OTC A208T case induced by OTC gene mutation and research on the prediction and simulation of the impact on protein function."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "preventing the synthesis of citrulline from carbamoyl phosphate and ornithine, and is characterized by a remarkable increase in blood ammonia."
    explanation: Clinical OTCD evidence links impaired citrulline synthesis to increased blood ammonia.
  - reference: PMID:32628763
    reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
    explanation: Human OTCD report summarizes the ammonia, glutamine, citrulline, and orotic-acid biochemical pattern.
  downstream:
  - target: Hyperammonemic cerebral injury via astrocyte swelling
    description: Systemic ammonia crosses into brain and is converted to glutamine, driving astrocyte swelling.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Brain ammonia entry
    - Astrocytic glutamine synthesis
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ammonia diffuses freely across the blood–brain barrier and is converted with alanine to glutamine by glutamine synthase."
      explanation: Clinical review evidence supports brain ammonia entry and glutamine synthesis upstream of astrocyte swelling.
  - target: Hyperammonemia
    description: Systemic ammonia accumulation manifests clinically as hyperammonemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39328593
      reference_title: "In-depth analysis of OTC A208T case induced by OTC gene mutation and research on the prediction and simulation of the impact on protein function."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "preventing the synthesis of citrulline from carbamoyl phosphate and ornithine, and is characterized by a remarkable increase in blood ammonia."
      explanation: Clinical OTCD report directly supports hyperammonemia downstream of impaired OTC-dependent citrulline synthesis.
  - target: Ammonia
    description: Impaired ureagenesis increases circulating ammonium/ammonia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39256843
      reference_title: "Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "elevated blood ammonia levels serve as a crucial diagnostic clue for OTCD"
      explanation: Patient cohort evidence identifies elevated blood ammonia as a diagnostic consequence of OTCD.
  - target: Glutamine
    description: Excess ammonia is detoxified through glutamine synthesis, increasing plasma and brain glutamine.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Ammonia detoxification by glutamine synthesis
    evidence:
    - reference: PMID:32628763
      reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
      explanation: Human OTCD report supports increased plasma ammonia and glutamine as linked biochemical hallmarks.
  - target: Hyperglutaminemia
    description: Ammonia detoxification burden produces clinically detectable hyperglutaminemia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Ammonia detoxification by glutamine synthesis
    evidence:
    - reference: PMID:39220945
      reference_title: "A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in Vietnam."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "all ten early-onset cases had glutamine concentrations above the upper limit"
      explanation: Clinical screening data support hyperglutaminemia in early-onset OTCD.
- name: Hyperammonemic cerebral injury via astrocyte swelling
  description: >
    Recurrent hyperammonemia causes astrocyte swelling and cerebral edema through
    glutamine accumulation. In brain, glutamine synthesis is the only route of
    ammonia detoxification, and excess glutamine acts as an osmolyte causing
    astrocyte swelling and cerebral edema.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  biological_processes:
  - preferred_term: L-glutamine metabolic process
    term:
      id: GO:0006541
      label: L-glutamine metabolic process
    modifier: INCREASED
  chemical_entities:
  - preferred_term: ammonium
    term:
      id: CHEBI:28938
      label: ammonium
    modifier: INCREASED
  - preferred_term: glutamine
    term:
      id: CHEBI:28300
      label: glutamine
    modifier: INCREASED
  evidence:
  - reference: PMID:36128655
    reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Its clinical manifestations are mainly central nervous system dysfunction caused by high blood ammonia."
    explanation: Supports ammonia-driven CNS injury as a core downstream mechanism.
  - reference: PMID:34665389
    reference_title: "Hyperammonemia in Inherited Metabolic Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "severe damage to the central nervous system due to the toxic effects exerted by ammonia on the astrocytes"
    explanation: Directly supports astrocyte-mediated ammonia neurotoxicity.
  - reference: PMID:35733937
    reference_title: "Dysregulation of Astrocytic Glutamine Transport in Acute Hyperammonemic Brain Edema."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in brain glutamine synthesis is the only route of ammonia detoxification, hyperammonemia is as a rule associated with increased brain glutamine content (glutaminosis)"
    explanation: Supports the glutamine trapping hypothesis and osmotic astrocyte swelling mechanism.
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%"
    explanation: Quantifies the high risk of cerebral edema at elevated ammonia levels in adults with UCD.
  downstream:
  - target: Ammonia-induced oxidative stress and mitochondrial dysfunction
    description: Ammonia and glutamine-driven astrocyte swelling promote downstream oxidative and mitochondrial stress in the CNS.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Brain glutamine accumulation
    - Astrocyte swelling
    evidence:
    - reference: PMID:35733937
      reference_title: "Dysregulation of Astrocytic Glutamine Transport in Acute Hyperammonemic Brain Edema."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "changes in glutamine transport link glutaminosis- evoked mitochondrial dysfunction to oxidative-nitrosative stress"
      explanation: Review evidence connects glutaminosis to mitochondrial dysfunction and oxidative-nitrosative stress.
  - target: Encephalopathy
    description: Ammonia-driven brain swelling and neurotransmission toxicity cause metabolic encephalopathy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hyperammonemia caused by a disorder of the urea cycle is a rare cause of metabolic encephalopathy"
      explanation: Systematic clinical review directly links UCD hyperammonemia to metabolic encephalopathy.
  - target: Cerebral edema
    description: Astrocytic glutamine accumulation acts osmotically, producing brain swelling and cerebral edema.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Astrocyte glutamine accumulation
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Glutamine is the main intracellular osmole of the brain. Its accumulation causes the swelling of astrocytes during hyperammonemia"
      explanation: Clinical review evidence supports glutamine-mediated astrocyte swelling as the proximate mechanism for cerebral edema.
  - target: Coma
    description: Severe hyperammonemic brain edema and intracranial hypertension can progress to coma.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Intracranial hypertension
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Intra cranial hypertension appears inducing coma, cerebral engagement and death of the patient."
      explanation: Clinical review evidence connects ammonia/glutamine-driven intracranial hypertension to coma.
  - target: Seizures
    description: Hyperammonemic neurologic injury can manifest with seizures in early-onset OTCD.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39256843
      reference_title: "Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure."
      explanation: Patient cohort evidence supports seizures during early-onset OTCD presentations.
  - target: Vomiting
    description: Hyperammonemic decompensation can begin with vomiting before deterioration in consciousness.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36128655
      reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma."
      explanation: Late-onset OTCD case evidence supports vomiting during hyperammonemic neurologic decompensation.
  - target: Lethargy
    description: Hyperammonemic CNS dysfunction reduces arousal and can progress to coma.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36128655
      reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma."
      explanation: Case evidence supports impaired consciousness during OTCD decompensation.
  - target: Behavioral abnormalities
    description: Slower or intermittent hyperammonemia can cause behavioral and psychiatric manifestations.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Increased serotonin production may contribute to behavioral abnormalities, migraine, headaches, and changes in cerebral blood flow"
      explanation: Clinical review evidence supports behavioral abnormalities during slower hyperammonemic states.
- name: Ammonia-induced oxidative stress and mitochondrial dysfunction
  description: >
    Hyperammonemia induces oxidative stress and mitochondrial dysfunction in the
    CNS, contributing to neuronal energy failure and cumulative neurodevelopmental
    impairment.
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: PMID:34665389
    reference_title: "Hyperammonemia in Inherited Metabolic Diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Ammonia is a neurotoxic compound which is detoxified through liver enzymes from urea cycle."
    explanation: Supports the neurotoxic role of ammonia when hepatic detoxification is impaired.
  downstream:
  - target: Global developmental delay
    description: Severe or recurrent hyperammonemic CNS injury can leave persistent neurodevelopmental sequelae.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37626723
      reference_title: "Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "hyperammonemic episodes, which can cause death or neurological sequelae"
      explanation: Review evidence supports neurologic sequelae after OTCD hyperammonemic episodes.
- name: Carbamoyl phosphate diversion to pyrimidine pathway
  description: >
    When OTC cannot utilize carbamoyl phosphate for citrulline synthesis,
    substrate shunting into pyrimidine synthesis produces urinary pyrimidine
    byproducts and contributes to increased urine orotic acid in OTCD.
  chemical_entities:
  - preferred_term: carbamoyl phosphate
    term:
      id: CHEBI:17672
      label: carbamoyl phosphate
    modifier: ABNORMAL
  - preferred_term: uracil
    term:
      id: CHEBI:17568
      label: uracil
    modifier: INCREASED
  - preferred_term: orotic acid
    term:
      id: CHEBI:16742
      label: orotic acid
    modifier: INCREASED
  evidence:
  - reference: PMID:32628763
    reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "UU can accumulate in UCDs, due to shunting of carbamoylphosphate to pyrimidine synthesis (Fig. 1)."
    explanation: OTCD case-based evidence supports carbamoylphosphate shunting into pyrimidine synthesis.
  - reference: PMID:32628763
    reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
    explanation: Human OTCD report supports increased urinary orotic acid as a major biochemical hallmark.
  downstream:
  - target: Uracil
    description: Carbamoylphosphate shunting to pyrimidine synthesis increases urinary uracil in OTCD.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Pyrimidine byproduct accumulation
    evidence:
    - reference: PMID:32628763
      reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "UU can accumulate in UCDs, due to shunting of carbamoylphosphate to pyrimidine synthesis (Fig. 1)."
      explanation: OTCD case-based evidence links carbamoylphosphate shunting to urinary uracil accumulation.
  - target: Orotic acid
    description: OTCD has increased urine orotic acid as part of the pyrimidine-diversion biochemical pattern.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Pyrimidine byproduct accumulation
    evidence:
    - reference: PMID:32628763
      reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
      explanation: Human OTCD report supports increased urinary orotic acid as a major biochemical hallmark.
  - target: Oroticaciduria
    description: Increased urinary orotic acid manifests clinically as oroticaciduria.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Increased urinary orotic acid
    evidence:
    - reference: PMID:32628763
      reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
      explanation: Human OTCD report supports increased urine orotic acid as a hallmark of OTCD.
phenotypes:
- name: Hyperammonemia
  frequency: VERY_FREQUENT
  description: Marked or intermittent plasma ammonia elevation, the cardinal biochemical feature.
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:31441224
    reference_title: "Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Maternal OTCD can lead to life-threatening hyperammonemia if untreated."
    explanation: Confirms hyperammonemia as a major clinical risk in OTCD.
  - reference: PMID:37146589
    reference_title: "The functional impact of 1,570 individual amino acid substitutions in human OTC."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with neonatal onset appear normal at birth but rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"
    explanation: Confirms hyperammonemia as the pivotal early clinical event in neonatal OTCD.
- name: Encephalopathy
  frequency: FREQUENT
  description: Acute encephalopathy during decompensation episodes.
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:36128655
    reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Its clinical manifestations are mainly central nervous system dysfunction caused by high blood ammonia."
    explanation: Supports encephalopathic CNS dysfunction in OTCD.
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hyperammonemia caused by a disorder of the urea cycle is a rare cause of metabolic encephalopathy that may be underdiagnosed by the adult intensivists because of its rarity."
    explanation: Directly identifies UCD-related hyperammonemia as a cause of metabolic encephalopathy.
- name: Vomiting
  frequency: FREQUENT
  description: Emesis associated with metabolic crisis and rising ammonia.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:36128655
    reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma."
    explanation: Directly supports vomiting as an early symptom in hyperammonemic decompensation.
- name: Lethargy
  frequency: FREQUENT
  description: Reduced arousal, progressing to coma in severe episodes.
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:36128655
    reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma."
    explanation: Supports severe neurologic decline during OTCD decompensation episodes.
- name: Seizures
  frequency: FREQUENT
  description: Seizures occurring during hyperammonemic crises.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:39256843
    reference_title: "Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure."
    explanation: Directly reports seizures as a clinical manifestation in early-onset OTCD.
- name: Coma
  frequency: FREQUENT
  description: Hyperammonemic coma during severe decompensation, particularly in neonatal-onset disease.
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:37146589
    reference_title: "The functional impact of 1,570 individual amino acid substitutions in human OTC."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"
    explanation: Directly supports coma as a progression of hyperammonemia in OTCD.
  - reference: PMID:36128655
    reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the disease progressed rapidly and finally resulted in a coma"
    explanation: Case report documenting progression to coma in late-onset OTCD.
- name: Cerebral edema
  frequency: FREQUENT
  description: >
    Brain swelling secondary to ammonia-driven astrocyte osmotic changes;
    risk exceeds 55% when ammonia levels surpass 200 micromol/L.
  phenotype_term:
    preferred_term: Cerebral edema
    term:
      id: HP:0002181
      label: Cerebral edema
  evidence:
  - reference: PMID:37146589
    reference_title: "The functional impact of 1,570 individual amino acid substitutions in human OTC."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"
    explanation: Directly names cerebral edema as a complication of hyperammonemia in OTCD.
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%"
    explanation: Quantifies the high risk of cerebral edema at severe ammonia levels.
- name: Global developmental delay
  frequency: OCCASIONAL
  description: Neurodevelopmental delay risk after recurrent or severe crises.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:36128655
    reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, the child is currently mentally retarded, and the language center has not yet fully recovered."
    explanation: Supports persistent neurodevelopmental impairment after severe OTCD CNS injury.
- name: Hepatic failure
  frequency: OCCASIONAL
  description: Liver failure may occur during severe metabolic decompensation, particularly in early-onset cases.
  phenotype_term:
    preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  evidence:
  - reference: PMID:39256843
    reference_title: "Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure."
    explanation: Directly reports liver failure as a clinical feature in early-onset OTCD.
- name: Hyperglutaminemia
  frequency: VERY_FREQUENT
  description: Elevated plasma glutamine from excess ammonia detoxification via glutamine synthetase.
  phenotype_term:
    preferred_term: Hyperglutaminemia
    term:
      id: HP:0003217
      label: Hyperglutaminemia
  evidence:
  - reference: PMID:39220945
    reference_title: "A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in Vietnam."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all ten early-onset cases had glutamine concentrations above the upper limit"
    explanation: Directly documents hyperglutaminemia in all early-onset OTCD cases.
- name: Oroticaciduria
  frequency: VERY_FREQUENT
  description: >
    Increased urinary orotic acid accompanying carbamoylphosphate shunting into
    pyrimidine synthesis; a distinguishing feature from CPS1 deficiency.
  phenotype_term:
    preferred_term: Oroticaciduria
    term:
      id: HP:0003218
      label: Oroticaciduria
  evidence:
  - reference: PMID:32410394
    reference_title: "Two novel mutations in the ornithine transcarbamylase gene of male infants with ornithine transcarbamylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The urinary orotic acid level was 132.92 μmol/mmol creatinine (reference: 0.0–1.5 μmol/mmol creatinine)."
    explanation: Infant OTCD case evidence supports markedly elevated urinary orotic acid.
  - reference: PMID:32628763
    reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
    explanation: Human OTCD report identifies increased urinary orotic acid as a major biochemical hallmark.
  notes: Oroticaciduria is a well-established diagnostic marker differentiating OTCD from CPS1 deficiency, with urinary pyrimidine byproducts reflecting carbamoylphosphate shunting to pyrimidine synthesis.
- name: Low plasma citrulline
  frequency: FREQUENT
  description: Reduced plasma citrulline reflecting impaired OTC enzymatic product formation.
  phenotype_term:
    preferred_term: Low plasma citrulline
    term:
      id: HP:0003572
      label: Low plasma citrulline
  evidence:
  - reference: PMID:39220945
    reference_title: "A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in Vietnam."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "only five of them had citrulline concentrations below the lower limit of the reference interval"
    explanation: Documents low citrulline in early-onset OTCD, though not universally present.
- name: Behavioral abnormalities
  frequency: OCCASIONAL
  description: >
    Psychiatric and behavioral disturbances including confusion, agitation,
    and psychotic-like episodes may be the presenting feature of late-onset disease.
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased serotonin production may contribute to behavioral abnormalities, migraine, headaches, and changes in cerebral blood flow"
    explanation: Clinical review evidence supports behavioral abnormalities in slower hyperammonemic states.
  notes: Behavioral disorders reported in 35% of adult-onset UCD presentations in systematic reviews.
genetic:
- name: OTC variants
  gene_term:
    preferred_term: OTC
    term:
      id: hgnc:8512
      label: OTC
  inheritance:
  - name: X-linked inheritance
    evidence:
    - reference: PMID:31441224
      reference_title: "Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: A systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder."
      explanation: Directly supports X-linked inheritance in OTCD.
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Urea cycle disorders are autosomal recessive diseases except for ornithine transcarbamylase deficiency (OTCD) that is X-linked."
      explanation: Confirms OTCD is the only X-linked UCD.
  features: >
    Pathogenic OTC variants produce variable severity from neonatal male
    presentations to later-onset or heterozygous female disease. A high-throughput
    functional assay of 1,570 OTC missense variants distinguished benign from
    pathogenic variants and correlated with neonatal versus late-onset presentations.
  evidence:
  - reference: PMID:31441224
    reference_title: "Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder."
    explanation: Supports OTC genetic etiology and inheritance architecture.
  - reference: PMID:37146589
    reference_title: "The functional impact of 1,570 individual amino acid substitutions in human OTC."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This rare but highly actionable disease can present with severe neonatal onset in males or with later onset in either sex."
    explanation: Supports genotype-phenotype correlation with variable onset and severity.
  - reference: PMID:37146589
    reference_title: "The functional impact of 1,570 individual amino acid substitutions in human OTC."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "our assay distinguishes known benign from pathogenic variants and variants with neonatal onset from late-onset disease presentation"
    explanation: Demonstrates functional assay-based classification of variant severity.
  - reference: PMID:39256843
    reference_title: "Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nine distinct variants of the OTC gene were identified, including two novel mutations"
    explanation: Expands the known OTC mutation spectrum with novel pathogenic variants.
- name: OTC
  gene_term:
    preferred_term: OTC
    term:
      id: hgnc:8512
      label: OTC
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_132fafbf-bb34-447c-9f6a-65803679eeb8-2019-10-29T181325.783Z
    reference_title: "OTC / ornithine carbamoyltransferase deficiency (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OTC | HGNC:8512 | ornithine carbamoyltransferase deficiency | MONDO:0010703 | XL | Definitive"
    explanation: ClinGen classifies the OTC-ornithine carbamoyltransferase deficiency gene-disease relationship as definitive with X-linked inheritance.
treatments:
- name: Protein-restricted diet
  description: Dietary nitrogen control tailored to age and growth requirements to reduce ammonia production.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Systemic ammonia accumulation
    treatment_effect: INHIBITS
    description: Protein restriction reduces nitrogen substrate load and lowers ammonia production pressure.
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the goal of treatment being to reduce ammonia production and accelerate elimination via alternative pathways"
      explanation: Systematic clinical review supports diet and treatment as ammonia-lowering strategies for urea-cycle defects.
  evidence:
  - reference: PMID:37626723
    reference_title: "Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "current dietary and medical treatments may not be sufficient to prevent hyperammonemic episodes"
    explanation: Supports dietary treatment as a standard component of OTCD management, though acknowledging its limitations.
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment consists in adapted nutrition, scavenging agents and dialysis."
    explanation: Confirms adapted nutrition as a core treatment component for UCD.
- name: Nitrogen scavenger therapy
  description: >
    Pharmacologic ammonia-scavenging agents (sodium benzoate, sodium
    phenylbutyrate, glycerol phenylbutyrate) for chronic and acute management.
  treatment_term:
    preferred_term: nitrogen scavenger therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sodium benzoate
      term:
        id: CHEBI:113455
        label: sodium benzoate
    - preferred_term: sodium phenylbutyrate
      term:
        id: CHEBI:75316
        label: sodium phenylbutyrate
    - preferred_term: glycerol phenylbutyrate
      term:
        id: CHEBI:134745
        label: glycerol phenylbutyrate
  target_mechanisms:
  - target: Impaired citrulline synthesis and reduced urea cycle flux
    treatment_effect: BYPASSES
    description: Nitrogen scavengers divert nitrogen into urinary excretion products that do not require normal urea-cycle flux.
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle"
      explanation: Clinical review evidence supports nitrogen scavengers as bypassing the urea cycle for nitrogen elimination.
  evidence:
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment consists in adapted nutrition, scavenging agents and dialysis."
    explanation: Confirms scavenging agents as a standard treatment modality.
  - reference: PMID:37626723
    reference_title: "Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "current dietary and medical treatments may not be sufficient to prevent hyperammonemic episodes"
    explanation: Supports pharmacologic treatment as standard care while noting its limitations.
- name: Arginine supplementation
  description: >
    L-arginine supplementation to provide substrate for the urea cycle
    downstream of the OTC block.
  treatment_term:
    preferred_term: nutritional supplementation
    term:
      id: MAXO:0000106
      label: nutritional supplementation
    therapeutic_agent:
    - preferred_term: L-arginine
      term:
        id: CHEBI:16467
        label: L-arginine
  target_mechanisms:
  - target: Impaired citrulline synthesis and reduced urea cycle flux
    treatment_effect: MODULATES
    description: Arginine supplementation supports downstream urea-cycle metabolites and limits proteolysis during impaired ureagenesis.
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Supplementation with L-Arginine or Citrulline is recommended to promote an alternative pathway of metabolism"
      explanation: Clinical review evidence supports arginine/citrulline supplementation as an alternative pathway support in UCD management.
  evidence:
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fifteen patients received l-arginine"
    explanation: Documents L-arginine use in the systematic review of adult UCD case reports.
- name: Acute hyperammonemia management
  description: >
    Rapid crisis-directed supportive management including protein restriction,
    glucose infusion, nitrogen scavengers, and emergent hemodialysis when ammonia
    exceeds 200 micromol/L.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_mechanisms:
  - target: Hyperammonemic cerebral injury via astrocyte swelling
    treatment_effect: INHIBITS
    description: Emergency dialysis and ammonia-lowering treatment reduce ammonia exposure to prevent brain edema and death.
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In hyperammonemia associated with urea cycle disorders, treatment with hemodialysis can reverse encephalopathy and prevent brain edema and death"
      explanation: Clinical review evidence supports hemodialysis as a mechanism-targeted acute intervention against hyperammonemic cerebral injury.
  evidence:
  - reference: PMID:31441224
    reference_title: "Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Maternal OTCD can lead to life-threatening hyperammonemia if untreated."
    explanation: Supports urgent supportive and ammonia-lowering intervention during crises.
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%"
    explanation: Provides clinical threshold for emergent hemodialysis in acute hyperammonemia.
- name: Liver transplantation
  description: >
    Curative metabolic option for selected severe phenotypes; restores full urea
    cycle capacity and eliminates hyperammonemic risk.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
  target_mechanisms:
  - target: Ornithine carbamoyltransferase molecular function deficiency
    treatment_effect: RESTORES
    description: Liver transplantation supplies hepatic urea-cycle capacity that corrects the ammonia metabolism defect.
    evidence:
    - reference: PMID:36128655
      reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "liver transplantation can fundamentally solve the problem of ammonia metabolism in the liver"
      explanation: OTCD liver-transplant case review supports restoration of hepatic ammonia metabolism.
  evidence:
  - reference: PMID:36128655
    reference_title: "Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For OTCD patients with central nervous system injury, liver transplantation can fundamentally solve the problem of ammonia metabolism in the liver and avoids further damage to the central nervous system caused by hyperammonemia."
    explanation: Directly supports liver transplantation as a disease-modifying option in severe OTCD.
  - reference: PMID:37626723
    reference_title: "Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "liver transplantation is the only curative choice but is not widely available due to donor shortage, the need for life-long immunosuppression and technical challenges"
    explanation: Confirms liver transplantation as the only curative treatment while noting practical limitations.
  - reference: PMID:39256843
    reference_title: "Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three patients survived, and two of them underwent liver transplantation."
    explanation: Documents liver transplantation as a life-saving intervention in OTCD.
- name: Genetic counseling
  description: >
    Genetic counseling for X-linked inheritance pattern, carrier testing in
    at-risk females, and prenatal/preconception planning.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:31441224
    reference_title: "Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Maternal OTCD is associated with high maternal and neonatal morbidity and mortality when diagnosis is made during pregnancy compared to when diagnosis is known prior to pregnancy."
    explanation: Strongly supports the value of pre-pregnancy diagnosis and genetic counseling for carrier females.
biochemical:
- name: Ammonia
  presence: Increased
  context: Hyperammonemia from impaired urea cycle in OTCD
  biomarker_term:
    preferred_term: ammonium
    term:
      id: CHEBI:28938
      label: ammonium
  readouts:
  - target: Systemic ammonia accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Blood ammonia reports the proximal failure of hepatic ammonia disposal
      caused by reduced OTC-dependent urea-cycle flux.
  - target: Hyperammonemia
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Blood ammonia is the direct biochemical readout of hyperammonemia.
  - target: Hyperammonemic cerebral injury via astrocyte swelling
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >
      Plasma ammonia severity tracks risk of hyperammonemic cerebral edema and
      neurologic injury.
  evidence:
  - reference: PMID:37146589
    reference_title: "The functional impact of 1,570 individual amino acid substitutions in human OTC."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with neonatal onset appear normal at birth but rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"
    explanation: Confirms hyperammonemia as the cardinal biochemical abnormality in OTCD.
  - reference: PMID:39256843
    reference_title: "Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "elevated blood ammonia levels serve as a crucial diagnostic clue for OTCD"
    explanation: Directly identifies elevated ammonia as a key diagnostic marker.
- name: Glutamine
  presence: Increased
  context: Elevated plasma glutamine from ammonia detoxification via glutamine synthetase
  biomarker_term:
    preferred_term: glutamine
    term:
      id: CHEBI:28300
      label: glutamine
  readouts:
  - target: Systemic ammonia accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >
      Elevated glutamine reports ammonia detoxification burden downstream of
      impaired ureagenesis.
  - target: Hyperglutaminemia
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Plasma glutamine is the direct biochemical readout of
      hyperglutaminemia.
  - target: Hyperammonemic cerebral injury via astrocyte swelling
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >
      Brain or plasma glutamine tracks the glutamine-osmolyte mechanism driving
      astrocyte swelling.
  evidence:
  - reference: PMID:39220945
    reference_title: "A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in Vietnam."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all ten early-onset cases had glutamine concentrations above the upper limit"
    explanation: Directly documents elevated glutamine in all early-onset OTCD cases.
  - reference: PMID:12136059
    reference_title: "Distinctly abnormal brain metabolism in late-onset ornithine transcarbamylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The glutamine (Gln) plus glutamate concentration was increased in four patients, which progressed in proportion to the clinical stage."
    explanation: Brain MRS data showing progressive glutamine accumulation correlating with clinical severity.
- name: Citrulline
  presence: Decreased
  context: Low or low-normal plasma citrulline from impaired OTC enzymatic product formation
  biomarker_term:
    preferred_term: citrulline
    term:
      id: CHEBI:18211
      label: citrulline
  readouts:
  - target: Impaired citrulline synthesis and reduced urea cycle flux
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Low citrulline reports reduced product formation at the OTC-catalyzed
      urea-cycle step.
  - target: Low plasma citrulline
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Plasma citrulline is the direct biochemical readout of low citrulline.
  evidence:
  - reference: PMID:39220945
    reference_title: "A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in Vietnam."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "only five of them had citrulline concentrations below the lower limit of the reference interval"
    explanation: Documents low citrulline in a proportion of early-onset OTCD cases.
  - reference: PMID:39220945
    reference_title: "A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in Vietnam."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Cit/Phe ratio was decreased, and the Gln/Cit and Met/Cit ratios were increased in all early-onset OTCD cases"
    explanation: Supports abnormal citrulline ratios as reliable screening markers.
- name: Uracil
  presence: Increased
  context: Increased urinary uracil accompanying carbamoylphosphate shunting to pyrimidine synthesis
  biomarker_term:
    preferred_term: uracil
    term:
      id: CHEBI:17568
      label: uracil
  readouts:
  - target: Carbamoyl phosphate diversion to pyrimidine pathway
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Urinary uracil reports carbamoyl phosphate shunting into pyrimidine
      synthesis when OTC flux is blocked.
  evidence:
  - reference: PMID:32628763
    reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Organic acids revealed increased urinary uracil (UU, 36 mg/g Cr)(RI:0-21) concerning for ornithine transcarbamylase deficiency (OTCD)."
    explanation: OTCD case evidence directly reports increased urinary uracil.
  - reference: PMID:32628763
    reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "UU may be more reliable than OA for late-onset OTCD during acute and quiescent phases."
    explanation: Human OTCD report supports urinary uracil as a useful biomarker, particularly in late-onset disease.
- name: Orotic acid
  presence: Increased
  context: Elevated urinary orotic acid accompanying carbamoylphosphate shunting to pyrimidine synthesis
  biomarker_term:
    preferred_term: orotic acid
    term:
      id: CHEBI:16742
      label: orotic acid
  readouts:
  - target: Carbamoyl phosphate diversion to pyrimidine pathway
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Elevated urinary orotic acid reports pyrimidine byproduct formation from
      carbamoyl phosphate diversion.
  - target: Oroticaciduria
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Urinary orotic acid is the direct biochemical readout of oroticaciduria.
  evidence:
  - reference: PMID:32410394
    reference_title: "Two novel mutations in the ornithine transcarbamylase gene of male infants with ornithine transcarbamylase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The urinary orotic acid level was 132.92 μmol/mmol creatinine (reference: 0.0–1.5 μmol/mmol creatinine)."
    explanation: Infant OTCD case evidence directly supports elevated urinary orotic acid.
  - reference: PMID:32628763
    reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA."
    explanation: Human OTCD report supports increased urine orotic acid as a hallmark biochemical abnormality.
  notes: Elevated urinary orotic acid in OTCD is part of a pyrimidine-byproduct pattern that helps distinguish OTCD from CPS1 deficiency.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Pathophysiology description
Edison Scientific Literature 29 citations 2026-02-23T23:16:26.883357

Pathophysiology description OTCD is an X-linked urea-cycle disorder caused by loss-of-function variants in OTC, a mitochondrial hepatocyte enzyme catalyzing carbamoyl phosphate + ornithine → citrulline. Blockade of ureagenesis causes episodic or persistent hyperammonemia. The brain detoxifies ammonia primarily via astrocytic glutamine synthetase, increasing glutamine (glutaminosis). Glutamine accumulation drives astrocyte osmotic swelling, cerebral edema, intracranial hypertension, seizures, coma, and potentially herniation/death; mitochondrial dysfunction, oxidative stress, and neurotransmitter disturbances amplify injury. Biomarker patterns include hyperammonemia, elevated glutamine (and often alanine), low citrulline (variable in DBS), and elevated urinary orotic acid. (yilmaz2023genetictherapyapproaches pages 1-2, lo2023thefunctionalimpact pages 1-3, redant2021managementoflate pages 1-3, ribas2022hyperammonemiaininherited pages 5-6, matsumoto2019ureacycledisorders—update pages 4-5)

Gene/protein annotations (HGNC) - OTC (X-linked; mitochondrial enzyme; hepatocyte expression) (yilmaz2023genetictherapyapproaches pages 1-2)

Cell type involvement (CL) - Hepatocyte (CL:0000182) — primary site of ureagenesis defect (yilmaz2023genetictherapyapproaches pages 1-2) - Astrocyte (CL:0000127) — ammonia→glutamine detoxification, swelling, edema (zielinska2022dysregulationofastrocytic pages 1-2, redant2021managementoflate pages 1-3)

Anatomical locations (UBERON) - Liver (UBERON:0002107) — primary site of defective ammonia detoxification (yilmaz2023genetictherapyapproaches pages 1-2) - Brain (UBERON:0000955) — site of ammonia neurotoxicity and edema (redant2021managementoflate pages 1-3)

Chemical entities (CHEBI) - Ammonia (CHEBI:16134); glutamine (CHEBI:28300); citrulline (CHEBI:16349); ornithine (CHEBI:15729); carbamoyl phosphate (CHEBI:17674); orotic acid (CHEBI:30845) (supported as key metabolites/biomarkers in text) (ribas2022hyperammonemiaininherited pages 5-6, matsumoto2019ureacycledisorders—update pages 4-5, hu2024indepthanalysisof pages 1-2)

  1. Limitations of this report (evidence availability)
  2. A MONDO identifier for OTCD was not present in the retrieved excerpts; therefore it is not asserted.
  3. Several mechanistic sections rely on peer-reviewed reviews that cite primary studies without listing PMIDs in the excerpt text; PMIDs are therefore not consistently recoverable from the tool context alone, though DOIs and full citations are provided.

References

  1. (OpenTargets Search: Ornithine carbamoyltransferase deficiency,Ornithine transcarbamylase deficiency-OTC): Open Targets Query (Ornithine carbamoyltransferase deficiency,Ornithine transcarbamylase deficiency-OTC, 8 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  2. (NCT05345171 chunk 2): Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency. Ultragenyx Pharmaceutical Inc. 2022. ClinicalTrials.gov Identifier: NCT05345171

  3. (yilmaz2023genetictherapyapproaches pages 1-2): Berna Seker Yilmaz and Paul Gissen. Genetic therapy approaches for ornithine transcarbamylase deficiency. Biomedicines, 11:2227, Aug 2023. URL: https://doi.org/10.3390/biomedicines11082227, doi:10.3390/biomedicines11082227. This article has 30 citations.

  4. (lo2023thefunctionalimpact pages 1-3): Russell S. Lo, Gareth A. Cromie, Michelle Tang, Kevin Teng, Katherine Owens, Amy Sirr, J. Nathan Kutz, Hiroki Morizono, Ljubica Caldovic, Nicholas Ah Mew, Andrea Gropman, and Aimée M. Dudley. The functional impact of 1,570 individual amino acid substitutions in human otc. American journal of human genetics, 110 5:863-879, May 2023. URL: https://doi.org/10.1016/j.ajhg.2023.03.019, doi:10.1016/j.ajhg.2023.03.019. This article has 28 citations and is from a highest quality peer-reviewed journal.

  5. (NCT03767270 chunk 1): Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency. Translate Bio, Inc.. 2019. ClinicalTrials.gov Identifier: NCT03767270

  6. (matsumoto2019ureacycledisorders—update pages 4-5): Shirou Matsumoto, Johannes Häberle, Jun Kido, Hiroshi Mitsubuchi, Fumio Endo, and Kimitoshi Nakamura. Urea cycle disorders—update. Journal of Human Genetics, 64:833-847, May 2019. URL: https://doi.org/10.1038/s10038-019-0614-4, doi:10.1038/s10038-019-0614-4. This article has 261 citations and is from a peer-reviewed journal.

  7. (hu2024indepthanalysisof pages 4-7): Qingyang Hu, Haiming Chen, Tianyi Liu, Xue-Tao Dong, Xuejiao Hu, Wenxin Yan, and Zhong Li. In-depth analysis of otc a208t case induced by otc gene mutation and research on the prediction and simulation of the impact on protein function. Frontiers in Pediatrics, Sep 2024. URL: https://doi.org/10.3389/fped.2024.1450859, doi:10.3389/fped.2024.1450859. This article has 2 citations.

  8. (ribas2022hyperammonemiaininherited pages 5-6): Graziela Schmitt Ribas, Franciele Fátima Lopes, Marion Deon, and Carmen Regla Vargas. Hyperammonemia in inherited metabolic diseases. Cellular and Molecular Neurobiology, 42:2593-2610, Oct 2022. URL: https://doi.org/10.1007/s10571-021-01156-6, doi:10.1007/s10571-021-01156-6. This article has 83 citations and is from a peer-reviewed journal.

  9. (nambiar2022acutefulminantencephalopathy pages 3-4): Vivek K. Nambiar, Aakash Shridharani, Sudheeran Kannoth, Siby Gopinath, and Anand Kumar. Acute fulminant encephalopathy in an adult due to ornithine transcarbamylase deficiency. Annals of Indian Academy of Neurology, 25:722-724, Jul 2022. URL: https://doi.org/10.4103/aian.aian_1028_21, doi:10.4103/aian.aian_1028_21. This article has 1 citations and is from a peer-reviewed journal.

  10. (hu2024indepthanalysisof pages 1-2): Qingyang Hu, Haiming Chen, Tianyi Liu, Xue-Tao Dong, Xuejiao Hu, Wenxin Yan, and Zhong Li. In-depth analysis of otc a208t case induced by otc gene mutation and research on the prediction and simulation of the impact on protein function. Frontiers in Pediatrics, Sep 2024. URL: https://doi.org/10.3389/fped.2024.1450859, doi:10.3389/fped.2024.1450859. This article has 2 citations.

  11. (ribas2022hyperammonemiaininherited pages 1-2): Graziela Schmitt Ribas, Franciele Fátima Lopes, Marion Deon, and Carmen Regla Vargas. Hyperammonemia in inherited metabolic diseases. Cellular and Molecular Neurobiology, 42:2593-2610, Oct 2022. URL: https://doi.org/10.1007/s10571-021-01156-6, doi:10.1007/s10571-021-01156-6. This article has 83 citations and is from a peer-reviewed journal.

  12. (zielinska2022dysregulationofastrocytic pages 1-2): Magdalena Zielińska, Jan Albrecht, and Mariusz Popek. Dysregulation of astrocytic glutamine transport in acute hyperammonemic brain edema. Frontiers in Neuroscience, Jun 2022. URL: https://doi.org/10.3389/fnins.2022.874750, doi:10.3389/fnins.2022.874750. This article has 22 citations and is from a peer-reviewed journal.

  13. (redant2021managementoflate pages 1-3): S. Redant, A. Empain, A. Mugisha, P. Kamgang, R. Attou, P. M. Honoré, and D. De Bels. Management of late onset urea cycle disorders—a remaining challenge for the intensivist? Annals of Intensive Care, Jan 2021. URL: https://doi.org/10.1186/s13613-020-00797-y, doi:10.1186/s13613-020-00797-y. This article has 41 citations and is from a peer-reviewed journal.

  14. (ribas2022hyperammonemiaininherited pages 2-4): Graziela Schmitt Ribas, Franciele Fátima Lopes, Marion Deon, and Carmen Regla Vargas. Hyperammonemia in inherited metabolic diseases. Cellular and Molecular Neurobiology, 42:2593-2610, Oct 2022. URL: https://doi.org/10.1007/s10571-021-01156-6, doi:10.1007/s10571-021-01156-6. This article has 83 citations and is from a peer-reviewed journal.

  15. (matsumoto2019ureacycledisorders—update pages 11-12): Shirou Matsumoto, Johannes Häberle, Jun Kido, Hiroshi Mitsubuchi, Fumio Endo, and Kimitoshi Nakamura. Urea cycle disorders—update. Journal of Human Genetics, 64:833-847, May 2019. URL: https://doi.org/10.1038/s10038-019-0614-4, doi:10.1038/s10038-019-0614-4. This article has 261 citations and is from a peer-reviewed journal.

  16. (takanashi2002distinctlyabnormalbrain pages 1-2): J. Takanashi, A. Kurihara, M. Tomita, M. Kanazawa, S. Yamamoto, F. Morita, H. Ikehira, S. Tanada, and Y. Kohno. Distinctly abnormal brain metabolism in late-onset ornithine transcarbamylase deficiency. Neurology, 59:210-214, Jul 2002. URL: https://doi.org/10.1212/wnl.59.2.210, doi:10.1212/wnl.59.2.210. This article has 69 citations and is from a highest quality peer-reviewed journal.

  17. (tran2024apreliminaryretrospective pages 2-4): Dien Minh Tran, Trang Thi Thu Tran, Quyen Hue Luong, and Mai Thi Chi Tran. A preliminary retrospective evaluation of screening and diagnosis of ornithine transcarbamylase deficiency in high-risk patients at a referral center in vietnam. Heliyon, 10:e36003, Aug 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e36003, doi:10.1016/j.heliyon.2024.e36003. This article has 0 citations.

  18. (yuan2024clinicalcharacteristicsand pages 2-3): Gaopin Yuan, Zhiyong Liu, Zhixu Chen, Xiaohong Zhang, Weifeng Zhang, and Dongmei Chen. Clinical characteristics and molecular genetic analysis of ten cases of ornithine carbamoyltransferase deficiency in southeastern china. Italian Journal of Pediatrics, Sep 2024. URL: https://doi.org/10.1186/s13052-024-01740-8, doi:10.1186/s13052-024-01740-8. This article has 0 citations and is from a peer-reviewed journal.

  19. (yilmaz2023genetictherapyapproaches pages 9-10): Berna Seker Yilmaz and Paul Gissen. Genetic therapy approaches for ornithine transcarbamylase deficiency. Biomedicines, 11:2227, Aug 2023. URL: https://doi.org/10.3390/biomedicines11082227, doi:10.3390/biomedicines11082227. This article has 30 citations.

  20. (matsumoto2019ureacycledisorders—update pages 9-10): Shirou Matsumoto, Johannes Häberle, Jun Kido, Hiroshi Mitsubuchi, Fumio Endo, and Kimitoshi Nakamura. Urea cycle disorders—update. Journal of Human Genetics, 64:833-847, May 2019. URL: https://doi.org/10.1038/s10038-019-0614-4, doi:10.1038/s10038-019-0614-4. This article has 261 citations and is from a peer-reviewed journal.

  21. (NCT05345171 chunk 1): Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency. Ultragenyx Pharmaceutical Inc. 2022. ClinicalTrials.gov Identifier: NCT05345171

  22. (NCT06488313 chunk 1): A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD. Arcturus Therapeutics, Inc.. 2024. ClinicalTrials.gov Identifier: NCT06488313

  23. (NCT05526066 chunk 1): Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810. Arcturus Therapeutics, Inc.. 2022. ClinicalTrials.gov Identifier: NCT05526066

  24. (NCT06255782 chunk 1): An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency. iECURE, Inc.. 2024. ClinicalTrials.gov Identifier: NCT06255782